NCT03596905View on ClinicalTrials.gov

Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)

PHASE2CompletedINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

October 14, 2024

Study Completion Date

November 25, 2024

Conditions

Irritable Bowel Syndrome With Constipation

Interventions

DRUG

Plecanatide

Taken orally daily for 4 weeks

DRUG

Matching placebo

Taken orally daily for 4 weeks

Trial Locations (11)

23606

Synergy Research Site, Newport News

33012

Synergy Research Site, Hialeah

33122

Synergy Research Site, Doral

33134

Synergy Research Site, Miami

33136

Synergy Research Site, Miami

33155

Synergy Research Site, Miami

33607

Synergy Research Site, Tampa

70526

Synergy Research Site, Crowley

77061

Synergy Research Site, Houston

78215

Synergy Research Site, San Antonio

92879

Synergy Research Site, Corona

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) | Biotech Hunter | Biotech Hunter